<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:12:31Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10946533" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10946533</identifier>
        <datestamp>2024-03-19</datestamp>
        <setSpec>blackwellopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="cea14251" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Clin Exp Allergy</journal-id>
              <journal-id journal-id-type="iso-abbrev">Clin Exp Allergy</journal-id>
              <journal-id journal-id-type="doi">10.1111/(ISSN)1365-2222</journal-id>
              <journal-id journal-id-type="publisher-id">CEA</journal-id>
              <journal-title-group>
                <journal-title>Clinical and Experimental Allergy</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0954-7894</issn>
              <issn pub-type="epub">1365-2222</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10946533</article-id>
              <article-id pub-id-type="pmcid">PMC10946533</article-id>
              <article-id pub-id-type="pmc-uid">10946533</article-id>
              <article-id pub-id-type="pmid">36385515</article-id>
              <article-id pub-id-type="pmid">36385515</article-id>
              <article-id pub-id-type="doi">10.1111/cea.14251</article-id>
              <article-id pub-id-type="publisher-id">CEA14251</article-id>
              <article-id pub-id-type="other">CEA-OA-2022-0244.R2</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Articles</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Progenitor cell‐derived basophils: A novel barcoded passive degranulation assay in allergic diseases</article-title>
                <alt-title alt-title-type="left-running-head">Wu et al.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="cea14251-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Wu</surname>
                    <given-names>Jiakai</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1494-5633</contrib-id>
                  <xref rid="cea14251-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="cea14251-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <address>
                    <email>jiakai.wu@manchester.ac.uk</email>
                  </address>
                </contrib>
                <contrib id="cea14251-cr-0002" contrib-type="author">
                  <name>
                    <surname>Bahri</surname>
                    <given-names>Rajia</given-names>
                  </name>
                  <xref rid="cea14251-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="cea14251-cr-0003" contrib-type="author">
                  <name>
                    <surname>Tsoumani</surname>
                    <given-names>Marina</given-names>
                  </name>
                  <xref rid="cea14251-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cea14251-cr-0004" contrib-type="author">
                  <name>
                    <surname>Semic‐Jusufagic</surname>
                    <given-names>Aida</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4232-1203</contrib-id>
                  <xref rid="cea14251-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cea14251-cr-0005" contrib-type="author">
                  <name>
                    <surname>Murray</surname>
                    <given-names>Clare S.</given-names>
                  </name>
                  <xref rid="cea14251-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="cea14251-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cea14251-cr-0006" contrib-type="author">
                  <name>
                    <surname>Custovic</surname>
                    <given-names>Adnan</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5218-7071</contrib-id>
                  <xref rid="cea14251-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="cea14251-cr-0007" contrib-type="author">
                  <name>
                    <surname>Guibas</surname>
                    <given-names>George V.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1294-1938</contrib-id>
                  <xref rid="cea14251-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cea14251-cr-0008" contrib-type="author">
                  <name>
                    <surname>Bennett</surname>
                    <given-names>Miriam</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0356-4365</contrib-id>
                  <xref rid="cea14251-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cea14251-cr-0009" contrib-type="author">
                  <name>
                    <surname>Wang</surname>
                    <given-names>Ran</given-names>
                  </name>
                  <xref rid="cea14251-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cea14251-cr-0010" contrib-type="author">
                  <name>
                    <surname>Gauvreau</surname>
                    <given-names>Gail</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6187-2385</contrib-id>
                  <xref rid="cea14251-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="cea14251-cr-0011" contrib-type="author">
                  <name>
                    <surname>Cusack</surname>
                    <given-names>Ruth</given-names>
                  </name>
                  <xref rid="cea14251-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="cea14251-cr-0012" contrib-type="author">
                  <name>
                    <surname>Mills</surname>
                    <given-names>Clare</given-names>
                  </name>
                  <xref rid="cea14251-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="cea14251-cr-0013" contrib-type="author">
                  <name>
                    <surname>Bulfone‐Paus</surname>
                    <given-names>Silvia</given-names>
                  </name>
                  <xref rid="cea14251-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="cea14251-cr-0014" contrib-type="author">
                  <name>
                    <surname>Simpson</surname>
                    <given-names>Angela</given-names>
                  </name>
                  <xref rid="cea14251-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="cea14251-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="cea14251-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences</named-content>
                <institution>University of Manchester</institution>
                <city>Manchester</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="cea14251-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust</named-content>
                <institution>Manchester Academic Health Science Centre</institution>
                <city>Manchester</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="cea14251-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Centre for Dermatological Research &amp; Manchester Collaborative Centre for Inflammation Research (MCCIR), School of Biological Sciences</named-content>
                <institution>University of Manchester</institution>
                <city>Manchester</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="cea14251-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">National Heart and Lung Institute</named-content>
                <institution>Imperial College London</institution>
                <city>London</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="cea14251-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Division of Respirology, Department of Medicine</named-content>
                <institution>McMaster University</institution>
                <city>Hamilton</city>
                <named-content content-type="country-part">Ontario</named-content>
                <country country="CA">Canada</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Jiakai Wu, Manchester Collaborative Centre for Inflammation Research (MCCIR), 2.11 Core Technology Facility, Grafton Street Manchester, M13 9NT, UK.<break/>
Email: <email>jiakai.wu@manchester.ac.uk</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>16</day>
                <month>11</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <volume>53</volume>
              <issue seq="50">4</issue>
              <issue-id pub-id-type="doi">10.1111/cea.v53.4</issue-id>
              <fpage>405</fpage>
              <lpage>416</lpage>
              <history>
                <date date-type="rev-recd">
                  <day>19</day>
                  <month>10</month>
                  <year>2022</year>
                </date>
                <date date-type="received">
                  <day>25</day>
                  <month>6</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>31</day>
                  <month>10</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <!--Copyright &#x000a9; 2023 John Wiley & Sons Ltd-->
                <copyright-statement content-type="article-copyright">© 2022 The Authors. <italic toggle="yes">Clinical &amp; Experimental Allergy</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:CEA-53-405.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="cea14251-sec-0001">
                  <title>Background</title>
                  <p>Effector cells assays provide an overall measure of responsiveness to allergen, but the lack of reliable and high‐throughput assays limits the clinical utility. We aimed to develop a high‐throughput basophil activation test based on human progenitor cell‐derived basophils (PCB) and investigate the role of PCB activation test (PCBAT) in allergic diseases.</p>
                </sec>
                <sec id="cea14251-sec-0002">
                  <title>Methods</title>
                  <p>Progenitor cell‐derived basophils were differentiated from CD34<sup>+</sup> progenitor cells and sensitized with sera from subjects sensitized to cat, peanut or atopic controls. Sensitized PCBs were stimulated with increasing concentrations of the corresponding allergens in vitro. Degranulation was assessed by measuring CD63 expression using flow cytometry. The correlations between PCBAT and clinical allergy were assessed.</p>
                </sec>
                <sec id="cea14251-sec-0003">
                  <title>Results</title>
                  <p>Following passive sensitization of the mature PCBs with serum and allergen stimulation, an allergen specific dose‐dependent increase in CD63 expression was observed. Sera from subjects sensitized to cat (<italic toggle="no">n</italic> = 35, of which 17 subjects had clinical reactivity quantified using inhaled allergen challenge), peanut allergic (<italic toggle="no">n</italic> = 30, of which 15 subjects had clinical reactivity validated using double blind, placebo controlled food challenges [DBPCFC]), peanut‐sensitized but tolerant subjects (<italic toggle="no">n</italic> = 5) were used to sensitize PCBs. PCBAT area under the curve (AUC) correlated with sIgE (<italic toggle="no">r</italic>
<sup>2</sup> = .49, <italic toggle="no">p</italic> = .001) in subjects sensitized to cat (sIgE ≥ 0.35KU/L). The provocation concentration of inhaled cat allergen (PC<sub>20</sub>) correlated with PCBAT AUC (<italic toggle="no">r</italic>
<sup>2</sup> = .33, <italic toggle="no">p</italic> = .016). In subjects sensitized to peanut, PCBAT AUC was highly correlated with sIgE to Ara h 2 (<italic toggle="no">r</italic>
<sup>2</sup> = .59, <italic toggle="no">p</italic> &lt; .0001). Peanut threshold cumulative dose during DBPCFC was negatively correlated with PCBAT AUC (<italic toggle="no">r</italic>
<sup>2</sup> = .57, <italic toggle="no">p</italic> = .001) and IgE to Ara h1 (<italic toggle="no">r</italic>
<sup>2</sup> = .55, <italic toggle="no">p</italic> = .007), but not with sIgE to whole peanut or Ara h2. All peanut‐sensitized but tolerant subjects showed no reaction to peanut on PCBAT.</p>
                </sec>
                <sec id="cea14251-sec-0004">
                  <title>Conclusion</title>
                  <p>Progenitor cell‐derived basophils activation test is a high‐throughput assay, which correlates with clinical allergy and may confer a powerful alternative tool in allergy testing.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="cea14251-kwd-0001">allergy diagnosis</kwd>
                <kwd id="cea14251-kwd-0002">asthma</kwd>
                <kwd id="cea14251-kwd-0003">basophil</kwd>
                <kwd id="cea14251-kwd-0004">cat allergy</kwd>
                <kwd id="cea14251-kwd-0005">challenge tests</kwd>
                <kwd id="cea14251-kwd-0006">flow cytometry</kwd>
                <kwd id="cea14251-kwd-0007">peanut allergy</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>JP Moulton Charitable Fundation</funding-source>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>
                    <institution-wrap>
                      <institution>Manchester Biomedical Research Centre
</institution>
                      <institution-id institution-id-type="doi">10.13039/100014653</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-0003">
                  <funding-source>
                    <institution-wrap>
                      <institution>Medical Research Council
</institution>
                      <institution-id institution-id-type="doi">10.13039/501100007155</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>G0601361 (2007‐2012)</award-id>
                  <award-id>MR/K002449/1 (2013‐2014)</award-id>
                  <award-id>MR/L012693/1 (2014‐2018)</award-id>
                </award-group>
                <award-group id="funding-0004">
                  <funding-source>North West Lung Centre Charity</funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="6"/>
                <table-count count="1"/>
                <page-count count="12"/>
                <word-count count="5866"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>April 2023</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.9 mode:remove_FC converted:18.03.2024</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="CEA14251-cit-2001"><string-name><surname>Wu</surname><given-names>J</given-names></string-name>, <string-name><surname>Bahri</surname><given-names>R</given-names></string-name>, <string-name><surname>Tsoumani</surname><given-names>M</given-names></string-name>, et al. <article-title>Progenitor cell‐derived basophils: A novel barcoded passive degranulation assay in allergic diseases</article-title>. <source>Clin Exp Allergy</source>. <year>2023</year>;<volume>53</volume>:<fpage>405</fpage>‐<lpage>416</lpage>. doi: <pub-id pub-id-type="doi">10.1111/cea.14251</pub-id>
<pub-id pub-id-type="pmid">36385515</pub-id>
</mixed-citation>
              </p>
            </notes>
          </front>
          <body id="cea14251-body-0001">
            <p>
              <boxed-text position="anchor" content-type="box" id="cea14251-blkfxd-0001">
                <caption>
                  <title>Key Messages</title>
                </caption>
                <p>
                  <list list-type="bullet" id="cea14251-list-0001">
                    <list-item id="cea14251-li-0001">
                      <p>Progenitor cell‐derived basophils are easy to set up, maturation takes &lt;3 weeks.</p>
                    </list-item>
                    <list-item id="cea14251-li-0002">
                      <p>Progenitor cell‐derived basophil activation test allows batch test serum reactivity to allergen.</p>
                    </list-item>
                    <list-item id="cea14251-li-0003">
                      <p>Progenitor cell‐derived basophil activation test results are significantly associated with allergen challenge test results.</p>
                    </list-item>
                  </list>
                </p>
              </boxed-text>
            </p>
            <sec id="cea14251-sec-0007">
              <label>1</label>
              <title>INTRODUCTION</title>
              <p>Sensitization to inhalant allergens such as house dust mites, cats and dogs, is commonly associated with asthma, but is neither necessary nor sufficient for disease expression. Similarly, a positive skin prick test (SPT) or IgE test to a food does not equate to clinical food allergy, and false positive results are common. Challenge testing (either oral food challenge or inhaled allergen challenge) can be offered to patients, but is time consuming, carries the risk of severe reaction and is not suitable for all patients. Therefore, tests with superior diagnostic accuracy than IgE that are safe to use in all patients would be of value in clinical practice, especially amongst patients sensitized to many allergens.</p>
              <p>Basophils and mast cells (MC) are the two primary effector cells in allergic responses,<xref rid="cea14251-bib-0001" ref-type="bibr"><sup>1</sup></xref> based on which several effector cell assays were developed.<xref rid="cea14251-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="cea14251-bib-0005" ref-type="bibr"><sup>5</sup></xref>, <xref rid="cea14251-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="cea14251-bib-0016" ref-type="bibr"><sup>16</sup></xref> Cellular degranulation triggers the release of preformed and newly synthesized mediators inducing a potent biological response in a sensitized person following allergen exposure.<xref rid="cea14251-bib-0002" ref-type="bibr"><sup>2</sup></xref> The two cell types may have different roles in an allergic response but this is poorly understood.<xref rid="cea14251-bib-0002" ref-type="bibr"><sup>2</sup></xref>, <xref rid="cea14251-bib-0003" ref-type="bibr"><sup>3</sup></xref> While basophils are found in the circulation, MC are localized in peripheral tissues. Hence, basophils are more accessible and are commonly used as cell models for studying allergy.<xref rid="cea14251-bib-0004" ref-type="bibr"><sup>4</sup></xref> However, basophils account for &lt;1% of blood leukocytes, making purification a challenge. To obviate the need for purification, the basophil activation test (BAT) was developed using fresh whole blood, analysed immediately.<xref rid="cea14251-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="cea14251-bib-0005" ref-type="bibr"><sup>5</sup></xref> Following stimulation of whole blood with allergen (or control), the responsiveness of the basophils can be quantified using fluorochrome‐coupled antibody markers of basophil activation (e.g. CD63 and CD203c) by flow cytometry. The advantage of the BAT is that it takes account of many factors, which influence basophil responsiveness to an allergen such as IgG4/IgE ratio,<xref rid="cea14251-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="cea14251-bib-0007" ref-type="bibr"><sup>7</sup></xref> heterogeneity of sIgE to allergen components,<xref rid="cea14251-bib-0008" ref-type="bibr"><sup>8</sup></xref> medication<xref rid="cea14251-bib-0009" ref-type="bibr"><sup>9</sup></xref> and innate responsiveness of the cells.<xref rid="cea14251-bib-0010" ref-type="bibr"><sup>10</sup></xref> The disadvantages are that blood needs to be analysed immediately after being drawn,<xref rid="cea14251-bib-0005" ref-type="bibr"><sup>5</sup></xref> requiring the allergy clinic to have instant access to a staffed flow cytometry facility. In addition, 10%–20% of people carry ‘non‐releaser’ basophils, which are non‐responsive in the BAT, despite having clinical allergy.<xref rid="cea14251-bib-0011" ref-type="bibr"><sup>11</sup></xref> Consequently, this test is not generally available for clinical diagnostics, but used only in specialist laboratories for hymenoptera venom and drug allergy testing.</p>
              <p>The passive BAT, which uses basophils from a donor that are passively sensitized with the serum from the patient, was developed as an alternative method that circumvents some of these problems.<xref rid="cea14251-bib-0012" ref-type="bibr"><sup>12</sup></xref> Stored serum samples from subjects can be analysed in batches, providing greater flexibility. This also allows humoral factors to be investigated separately from cellular factors.<xref rid="cea14251-bib-0007" ref-type="bibr"><sup>7</sup></xref> However, the donors' basophils must be stripped of endogenous IgE with a mild acid treatment before the cells can be passively sensitized with patient serum samples, which can damage the donor basophils and lead to auto‐basophil activation<xref rid="cea14251-bib-0013" ref-type="bibr"><sup>13</sup></xref> and reduced sensitivity.<xref rid="cea14251-bib-0014" ref-type="bibr"><sup>14</sup></xref> Due to these limitations, passive BAT has only been used in a few studies. Although the passively sensitized approach has also been used on basophilic cell lines such as RBL‐2H3, there are a number of disadvantages, including the gradual loss of cell responsiveness within weeks of cultures.<xref rid="cea14251-bib-0015" ref-type="bibr"><sup>15</sup></xref>
</p>
              <p>To overcome the limitations of existing effector cell assays using basophils, this study we demonstrate a method of generating functional progenitor cell‐derived basophils (PCBs), and how they can be used to develop a reproducible, flow cytometry‐based basophil activation test (PCBAT) by passively sensitizing the PCBs with sera from cat or peanut‐sensitized patients. A detailed characterization of basophil differentiation, and demonstrate the functionality and reproducibility of this technique is provided. The potential clinical application of progenitor cell basophil activation test (PCBAT) is then explored by passively sensitizing the cells with sera from five groups of patients with allergic asthma and food allergy and testing degranulation to two allergens (cat and peanut).</p>
            </sec>
            <sec sec-type="methods" id="cea14251-sec-0008">
              <label>2</label>
              <title>METHODS</title>
              <sec id="cea14251-sec-0009">
                <label>2.1</label>
                <title>Study design</title>
                <p>We developed a new high‐throughput BAT, using basophils generated from peripheral blood progenitor cells from healthy donors—the PCBAT. To assess the potential clinical utility, serum samples from cat or peanut‐sensitized patients were used to passively sensitize the basophils. The sensitized PCBs were incubated with increasing concentrations of cat or peanut allergens and basophil activation was assessed by measuring CD63 expression using flow cytometry. The associations between the degree of basophil activation and clinical characteristics of the study participants were then assessed.</p>
              </sec>
              <sec id="cea14251-sec-0010">
                <label>2.2</label>
                <title>Materials</title>
                <sec id="cea14251-sec-0011">
                  <label>2.2.1</label>
                  <title>Development of progenitor cells‐derived basophil activation test (<styled-content style="fixed-case" toggle="no">PCBAT</styled-content>)</title>
                  <sec id="cea14251-sec-0012">
                    <title>Generating <styled-content style="fixed-case" toggle="no">PCBs</styled-content>
</title>
                    <p>Peripheral blood mononuclear cells (PBMCs) were isolated from leukocyte cones (NHS Blood and Transplant Centre, Manchester) using Ficoll density gradient centrifugation. CD34<sup>+</sup> haematopoietic progenitor cells were isolated by a magnetic bead method according to manufacturer's instructions (MACS Miltenyl Biotec). Purified CD34<sup>+</sup> haematopoietic progenitor cells were diluted to 1 × 10<sup>5</sup> cells/ml and cultured in Stemspan™ supplemented with 10 ng/ml IL‐3, 100 ng/ml SCF, 50 ng/ml IL‐6, 5 mg/ml human LDL and penicillin/streptomycin (100 U/ml). This was day 0 of culture, cell density was then maintained between 2–5 × 10<sup>5</sup>/ml up to day 28 at 37°C with 5% CO<sub>2</sub>.</p>
                  </sec>
                  <sec id="cea14251-sec-0013">
                    <title><styled-content style="fixed-case" toggle="no">PCBs</styled-content> characterization</title>
                    <p>To monitor the differentiation process, the culture was sampled at day 7, 10, 16, 21 and 28. The cells were characterized using flow cytometry, immunofluorescence and metachromatic staining and by functional assay (PCBAT). This was repeated on two separate donors.</p>
                  </sec>
                  <sec id="cea14251-sec-0014">
                    <title>Flow cytometry</title>
                    <p>Cell staining was performed on a 96‐well plate using approximately 5 × 10<sup>4</sup> cells/well. For PCB characterization, cells were stained with the following antibodies: CD63 (APC), CD123 (Percp‐Cy5.5), CD117 (BV605), CD203c (FITC), HLADR (eFluro450) and FcεRI (PE‐Cy7) for 20 min at 4°C. A detailed protocol including intracellular staining for 2D7 (PE) and fluorescence barcoding can be found in this article's online repository and gating strategy can be found in Figures <xref rid="cea14251-supitem-0001" ref-type="supplementary-material">S1 and S2</xref>.</p>
                  </sec>
                  <sec id="cea14251-sec-0015">
                    <title>Immunofluorescence staining</title>
                    <p>Cells were fixed in 4% paraformaldehyde and permeabilized with 0.1% tween and 10% goat serum. Cells were then stained in mouse anti‐BB1 antibody (1:10) followed by Alexa Fluor 555 goat anti‐mouse secondary antibody (1:200). Slides were mounted with fluoroshield mountant containing DAPI for cell nuclear staining and examined under a Leica DM IL LED microscope using Leica Application Suite software (Leica, UK).</p>
                  </sec>
                </sec>
              </sec>
              <sec id="cea14251-sec-0016">
                <label>2.3</label>
                <title>Validation and performance of <styled-content style="fixed-case" toggle="no">PCBAT</styled-content>
</title>
                <sec id="cea14251-sec-0017">
                  <label>2.3.1</label>
                  <title>Study subjects</title>
                  <p>Five groups with different clinical characteristics were identified and described in Table <xref rid="cea14251-tbl-0001" ref-type="table">1</xref>. All subjects provided written informed consent (North West ‐ Haydock Research Ethics Committee, REC reference 20/NW/0302; MAAS cohort registration: ICRCTN72673620 detailed elsewhere<xref rid="cea14251-bib-0016" ref-type="bibr"><sup>16</sup></xref>; Hamilton Integrated Research Ethics Board, project number 5394).</p>
                  <table-wrap position="float" id="cea14251-tbl-0001" content-type="TABLE">
                    <label>TABLE 1</label>
                    <caption>
                      <p>Demographic description of the study groups</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <thead valign="bottom">
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1"/>
                          <th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1"/>
                          <th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1"/>
                          <th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Sensitized subjects</th>
                          <th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Non‐sensitized control subjects</th>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" valign="bottom" rowspan="1" colspan="1">Group number</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1">Allergen used in PCBAT</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1">Study group description</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1">
                            <italic toggle="yes">n</italic>
                          </th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1">Age (years, Mean, ±SD)</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1">Gender (% male)</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1">sIgE (ku/L, Mean, ±SD)</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1">
                            <italic toggle="yes">n</italic>
                          </th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1">Age (years, Mean, ±SD)</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1">gender (% male)</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1">sIgE (ku/L)</th>
                        </tr>
                      </thead>
                      <tbody valign="top">
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Cat</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Sensitized to cat</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">18<xref rid="cea14251-note-0001" ref-type="table-fn"><sup>a</sup></xref>
</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">41.2 (15.2)</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">72.2%</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">12.10 (24.52)</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">6<xref rid="cea14251-note-0001" ref-type="table-fn"><sup>a</sup></xref>
</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">61.0 (21.3)</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">33.3%</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.4</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">2</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Cat</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Asthma, on Omalizumab, sensitized to inhalant allergens</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">4<xref rid="cea14251-note-0001" ref-type="table-fn"><sup>a</sup></xref>
</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">45.9 (14.7)</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">100%</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">36.05 (47.52)</td>
                          <td align="left" colspan="4" valign="top" rowspan="1">N/A</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">3</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Cat</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Clinical reactivity quantified with inhaled allergen challenge to cat</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">17<xref rid="cea14251-note-0002" ref-type="table-fn"><sup>b</sup></xref>
</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">38.1 (15.6)</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">52.9%</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">6<xref rid="cea14251-note-0001" ref-type="table-fn"><sup>a</sup></xref>
</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">49.5 (9.9)</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">33.3%</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.4</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Peanut</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Doctor diagnosed peanut allergy (clinical reactivity quantified using oral food challenge for 15 subjects, see OLS for details)</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">30<xref rid="cea14251-note-0001" ref-type="table-fn"><sup>a</sup></xref>
</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">24.5 (7.3)</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">46.7%</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">36.99 (38.60)</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">4<xref rid="cea14251-note-0001" ref-type="table-fn"><sup>a</sup></xref>
</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">44.8 (5.1)</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">50%</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.4</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">5</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Peanut</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Sensitization to 1 or more peanut allergen components, but self‐reported ingestion indicating oral tolerance</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">5<xref rid="cea14251-note-0003" ref-type="table-fn"><sup>c</sup></xref>
</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">16.0 (1.2)</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">40%</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
                          <td align="left" colspan="4" valign="top" rowspan="1">N/A</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot id="cea14251-ntgp-0001">
                      <fn id="cea14251-note-0001">
                        <label>
                          <sup>a</sup>
                        </label>
                        <p>Patients recruited from ManARTS biobank (Rec reference: <xref rid="cea14251-bib-0020" ref-type="bibr">20</xref>/NW/0302).</p>
                      </fn>
                      <fn id="cea14251-note-0002">
                        <label>
                          <sup>b</sup>
                        </label>
                        <p>From McMaster University, Ontario, Canada.</p>
                      </fn>
                      <fn id="cea14251-note-0003">
                        <label>
                          <sup>c</sup>
                        </label>
                        <p>From the population birth cohort—Manchester Asthma and Allergy Study (MAAS, registration: ICRCTN72673620) detailed elsewhere.<xref rid="cea14251-bib-0016" ref-type="bibr"><sup>16</sup></xref>
</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                </sec>
                <sec id="cea14251-sec-0018">
                  <label>2.3.2</label>
                  <title>Measurement of sensitization to cat and peanut allergens</title>
                  <p>Serum sIgE to cat was measured in Groups 1 and 2 subjects and sensitization was defined as sIgE ≥0.35 kU/L. SPT to cat allergen were performed in Group 3 subjects with a positive test defined as a wheal of 3 × 3 mm or greater. sIgE to peanut and peanut components allergens Ara h 1, 2, 3, 8, 9 (Immunocap, ThermoFisher Scientifc, Sweden) were measured in Group 4 and sIgE to Ara h 1, 2, 3, 6, 8, 9 were measured using ISAC (ThermoFisher Scientifc, Sweden) in Group 5 subjects (a positive result was defined as sIgE &gt; 0.3 ISU‐E).</p>
                </sec>
                <sec id="cea14251-sec-0019">
                  <label>2.3.3</label>
                  <title>Inhaled cat allergen challenge</title>
                  <p>Seventeen cat sensitized adults underwent inhaled cat allergen challenge at McMaster University, Ontario, using Cockcroft methods described previously<xref rid="cea14251-bib-0017" ref-type="bibr"><sup>17</sup></xref> (see Online Repository). Briefly, participants inhaled cat allergen at increasing concentrations until the forced expiratory volume within 1 s (FEV<sub>1</sub>) dropped by ≥20% from baseline. The provocation concentrations eliciting 20% fall in FEV1 were calculated (PC<sub>20</sub>).</p>
                </sec>
                <sec id="cea14251-sec-0020">
                  <label>2.3.4</label>
                  <title>Oral peanut challenge</title>
                  <p>Of 30 physician‐confirmed peanut allergic patients, 15 underwent double blind, placebo controlled food challenges (DBPCFC) to peanut<xref rid="cea14251-bib-0018" ref-type="bibr"><sup>18</sup></xref> (challenge protocol in the article's Online Repository). Participants ingested increasing quantities of peanut protein until objective signs of an allergic reaction were shown. The cumulative dose of peanut required to show first objective sign was used as a measure of clinical reactivity to peanut allergen.</p>
                </sec>
                <sec id="cea14251-sec-0021">
                  <label>2.3.5</label>
                  <title>PCBAT</title>
                  <p>Progenitor cell‐derived basophils were sensitized with either 20% patients' sera or with human myeloma IgE (1 μg/ml) overnight at 37°C with 5% CO<sub>2</sub>. On the follow day, allergens extracts of different dilutions were freshly prepared from the stock using fully supplemented culture media. Sensitized PCBs were activated by incubating with serial dilutions of extracts (roasted peanut extracts or cat allergen) in the presence of serum for 30 min at 37°C. Anti‐IgE (1 μg/ml) and ‘medium only’ was included for every subject as positive and negative controls, respectively. PCBs were identified by staining the cells with CD203c<sup>+</sup>(FITC) and FcεRI<sup>+</sup>(PE‐Cy7). CD63 (PE) was used as a degranulation marker. After cells were stained with antibodies and viability dyes, Fluorescent barcoding (16‐plex) was performed using methods previously described,<xref rid="cea14251-bib-0019" ref-type="bibr"><sup>19</sup></xref> detailed barcoding protocol can be found in this article's online repository. A minimum 5% of CD63 positive cells were required to indicate a positive PCBAT response. To depict the responsiveness of the PCBAT, we present results as AUC for CD63 expression at increasing allergen concentrations.</p>
                </sec>
                <sec id="cea14251-sec-0022">
                  <label>2.3.6</label>
                  <title>Statistics</title>
                  <p>Demographic variables were presented as means and standard deviation. The AUC was calculated using the trapezoidal rule on logarithmically transformed allergen concentrations to quantify the responsiveness of a degranulation assay, as previously described.<xref rid="cea14251-bib-0020" ref-type="bibr"><sup>20</sup></xref> Methods for EC50, CDsens and CDmax calculation are described in this articles' Online Repository. Correlations were assessed using Spearman R test for non‐parametric data and Pearson R test for normally distributed data (SPSS v22, IBM, Armonk, USA). A 2‐sided <italic toggle="yes">p</italic> value ≤ .05 was considered statistically significant.</p>
                </sec>
              </sec>
            </sec>
            <sec sec-type="results" id="cea14251-sec-0023">
              <label>3</label>
              <title>RESULTS</title>
              <sec id="cea14251-sec-0024">
                <label>3.1</label>
                <title><styled-content style="fixed-case" toggle="no">PCBAT</styled-content> development</title>
                <sec id="cea14251-sec-0025">
                  <label>3.1.1</label>
                  <title>Characterization of <styled-content style="fixed-case" toggle="no">PCBs</styled-content> maturity</title>
                  <p>Human primary PCBs were differentiated from CD34<sup>+</sup> haematopoietic progenitors following 28 days of culture. The maturity of PCBs was demonstrated using four methods ‐ immunophenotyping (Figure <xref rid="cea14251-fig-0001" ref-type="fig">1A–C</xref>), immunofluorescence staining (Figure <xref rid="cea14251-fig-0001" ref-type="fig">1D</xref>), functional tests (Figure <xref rid="cea14251-fig-0001" ref-type="fig">1</xref> E) and morphological study (Figure <xref rid="cea14251-supitem-0001" ref-type="supplementary-material">S3</xref>) for PCBs obtained from two donors (donor A in Figure <xref rid="cea14251-fig-0001" ref-type="fig">1</xref> and donor B in Figure <xref rid="cea14251-supitem-0001" ref-type="supplementary-material">S4</xref>).</p>
                  <fig position="float" fig-type="FIGURE" id="cea14251-fig-0001">
                    <label>FIGURE 1</label>
                    <caption>
                      <p>Characterization of PCBs differentiation during day 7–28 of culture. (A–C) Representative figures for non‐stimulated controls showing expression of basophil selection markers 2D7<sup>+</sup>/FcεRI<sup>+</sup>/CD117<sup>−</sup>/HLADR<sup>−</sup> during culture. (D) Parallel analysis of BB1 expression by immunofluorescence staining. (E) Degranulation capability by stimulating IgE sensitized cells with anti‐IgE during culture. Gating strategies were the same as illustrated in A–C.</p>
                    </caption>
                    <graphic xlink:href="CEA-53-405-g005" position="anchor" id="jats-graphic-1"/>
                  </fig>
                  <p>Mature PCBs were defined as 2D7<sup>+</sup>/FcεRI<sup>+</sup>/CD117<sup>−</sup>/HLADR<sup>−</sup> cells. The proportion of cells expressing the basophil marker 2D7 increased from day 7 (32.8%) peaked at day 16 (42.8%) and fell to 22.1% by day 28 (Figure <xref rid="cea14251-fig-0001" ref-type="fig">1A</xref>). When the 2D7<sup>+</sup> cells were gated for FcεRI<sup>+</sup>, the majority (~80%) were positive through the culture (Figure <xref rid="cea14251-fig-0001" ref-type="fig">1B</xref>). Furthermore, as the cells matured, the highest negativity for CD117<sup>−</sup> and HLADR<sup>−</sup> were seen at day 16 (Figure <xref rid="cea14251-fig-0001" ref-type="fig">1C</xref>). However, by day 28, the cells started to gain CD117 receptor expression, an additional indication that the culture was losing basophilic characteristics.</p>
                  <p>We performed immunofluorescence staining with another basophil marker, BB1. The BB1 positive cells were faintly visible at day 7, but clearly visible by day 16 and remained visible to day 28 (Figure <xref rid="cea14251-fig-0001" ref-type="fig">1D</xref>).</p>
                  <p>We tested the PCBs' ability to degranulate upon engagement of the FcεRI by sensitizing them with human myeloma IgE followed by anti‐IgE stimulation. The percentage of basophil activity, as measured by CD63 expression, increased as the cells matured, such that by day 16, 36.5% of cells showed degranulation (Figure <xref rid="cea14251-fig-0001" ref-type="fig">1E</xref>). This was repeated with PCBs from 4 other donors and showed a consistent percentage of activation between donors at day 16 (mean ± SEM: 41.31% ± 3.34, Figures <xref rid="cea14251-supitem-0001" ref-type="supplementary-material">S5A</xref>,B). The maturation of PCBs and degranulation capability at each stage was very similar between the two donors (Figure <xref rid="cea14251-fig-0001" ref-type="fig">1</xref>, Figures <xref rid="cea14251-supitem-0001" ref-type="supplementary-material">S4</xref> and <xref rid="cea14251-supitem-0001" ref-type="supplementary-material">S5C</xref>). Unstimulated control at each stage can be found at Figure <xref rid="cea14251-supitem-0001" ref-type="supplementary-material">S5E</xref>. Representative figures for cell viability through culture were shown at Figure <xref rid="cea14251-supitem-0001" ref-type="supplementary-material">S5D</xref>.</p>
                  <p>Using this method, an average yield (from nine donors) of 2.27 × 10<sup>7</sup> cells (9 × 10<sup>6</sup> ‐ 4.8 × 10<sup>7</sup>, minimum‐maximum) could be achieved at day 16 of culture, of which 25%–50% were basophils (Figure <xref rid="cea14251-supitem-0001" ref-type="supplementary-material">S8</xref>). May‐Grünwald Giemsa staining performed on day 16 cells showed heavily granulated cells (Figure <xref rid="cea14251-supitem-0001" ref-type="supplementary-material">S3</xref>).</p>
                  <p>The combined use of immunophenotyping, immunofluorescence, morphological characterization and functional tests suggested that the optimal window for PCBs was between day 16 and day 21. After day 21, cells began to lose basophilic features but still retained a high response to anti‐IgE following IgE sensitization (Figure <xref rid="cea14251-fig-0001" ref-type="fig">1A,E</xref>).</p>
                </sec>
                <sec id="cea14251-sec-0026">
                  <label>3.1.2</label>
                  <title>High‐throughput <styled-content style="fixed-case" toggle="no">PCBAT</styled-content> with fluorescent barcoding</title>
                  <p>To increase the throughput, we incorporated fluorescent barcoding to the PCBAT (Figures <xref rid="cea14251-supitem-0001" ref-type="supplementary-material">S6 and S7</xref>). We simplified the gating strategies for selecting PCB population to minimize the interference between fluorescence dyes and the antibody panel. We selected CD203c<sup>+/</sup>FcεRI<sup>+</sup> cells for the degranulation assay, as CD203c<sup>+</sup> cells were &gt;99% 2D7<sup>+</sup> (Figure <xref rid="cea14251-supitem-0001" ref-type="supplementary-material">S8</xref>). In addition, amongst CD203c<sup>+</sup> cells, only FcεRI<sup>+</sup> population could degranulate in response to FcεRI crosslinking (Figure <xref rid="cea14251-supitem-0001" ref-type="supplementary-material">S9</xref>).</p>
                </sec>
                <sec id="cea14251-sec-0027">
                  <label>3.1.3</label>
                  <title><styled-content style="fixed-case" toggle="no">PCBAT</styled-content> in cat allergy</title>
                  <p>Patient demographics and clinical characteristics are summarized in Table <xref rid="cea14251-tbl-0001" ref-type="table">1</xref>. PCBAT, sIgE and SPT results are presented in Tables <xref rid="cea14251-supitem-0001" ref-type="supplementary-material">S1–S4</xref>. All samples responded to positive control stimulant (anti‐IgE) and not to negative control stimulant (medium only). Results for sensitivity (EC50 and CDsens) and reactivity (CDmax) of the PCBAT are presented in Tables <xref rid="cea14251-supitem-0001" ref-type="supplementary-material">S1–S5</xref>.</p>
                  <sec id="cea14251-sec-0028">
                    <title><styled-content style="fixed-case" toggle="no">PCBAT</styled-content> and <styled-content style="fixed-case" toggle="no">sIgE</styled-content> in cat sensitized asthma patients</title>
                    <p>All but one (94.4%) cat sensitized patients (Group 1, <italic toggle="yes">n</italic> = 18) showed positive responses in PCBAT (Figure <xref rid="cea14251-fig-0002" ref-type="fig">2A</xref>). There was a significant correlation between PCBAT AUC and sIgE to cat (<italic toggle="yes">r</italic>
<sup>2</sup> = .49, <italic toggle="yes">p</italic> = .001; Figure <xref rid="cea14251-fig-0002" ref-type="fig">2B</xref>). Five of the six control subjects with asthma who were not sensitized to cat showed a negative response in PCBAT (Figure <xref rid="cea14251-fig-0002" ref-type="fig">2C</xref>). One control subject showed a weak positive response at the highest concentration. No response to cat allergen was observed in PCBAT in patients who were receiving omalizumab (<italic toggle="yes">n</italic> = 4, of which three were sensitized to cat [Group 2, Figure <xref rid="cea14251-fig-0002" ref-type="fig">2D</xref>]).</p>
                    <fig position="float" fig-type="FIGURE" id="cea14251-fig-0002">
                      <label>FIGURE 2</label>
                      <caption>
                        <p>PCBAT with cat allergen extracts on cat sensitized but clinical reactivity not validated subjects. PCBAT using cat allergen extracts from ALK (dilution factor 1:250; 1:1250; 1:6250; 1:31,250; 1:156,250 and 1:781,250) were performed on (A) 18 cat sensitized but clinical reactivity not validated subjects; (B) the relationship between the PCBAT AUC from the sensitized groups and the corresponding sIgE level were shown in scatter plot. (C) PCBAT using cat allergen extracts were also performed on six atopic but non‐cat sensitized subjects and (D) 4 subjects who are sensitized to cat allergen but under omalizumab treatment, spearman test and <italic toggle="yes">R</italic> square was calculated and <italic toggle="yes">p</italic> &lt; .05 were considered significant.</p>
                      </caption>
                      <graphic xlink:href="CEA-53-405-g004" position="anchor" id="jats-graphic-3"/>
                    </fig>
                  </sec>
                  <sec id="cea14251-sec-0029">
                    <title><styled-content style="fixed-case" toggle="no">PCBAT</styled-content> in predicting inhaled cat allergen challenge</title>
                    <p>Seventeen adults demonstrated airway reactivity during inhaled cat allergen challenge (Group 3). The median (IQR) of SPT wheal size was 6 (4–7.6) mm (Table <xref rid="cea14251-supitem-0001" ref-type="supplementary-material">S4</xref>) and the range for allergen PC<sub>20</sub> was large (median [IQR]: 102.5 [32.8–286.9] BAU/ml; Figure <xref rid="cea14251-supitem-0001" ref-type="supplementary-material">S10B</xref>). Of the 17 subjects, 15 showed a positive response on PCBAT (Figure <xref rid="cea14251-fig-0003" ref-type="fig">3A</xref>), two subjects showed no response. PCBAT AUC significantly correlated with ln(PC<sub>20</sub> cat allergen) (<italic toggle="yes">r</italic>
<sup>2</sup> = .33, <italic toggle="yes">p</italic> = .016; Figure <xref rid="cea14251-fig-0003" ref-type="fig">3B</xref>) but SPT wheal sizes did not (<italic toggle="yes">p</italic> = .230). All control subjects (<italic toggle="yes">n</italic> = 6) showed no response in PCBAT (Figure <xref rid="cea14251-fig-0003" ref-type="fig">3C</xref>).</p>
                    <fig position="float" fig-type="FIGURE" id="cea14251-fig-0003">
                      <label>FIGURE 3</label>
                      <caption>
                        <p>PCBAT with cat allergen extracts on cat allergic subjects validated with inhalant allergen challenge. PCBAT using cat allergen extracts from HollisterStier (dilution factor 1:250; 1:1250; 1:6250; 1:31,250; 1:156,250 and 1:781,250) were performed on (A) 17 clinal reactivity validated cat allergic subjects; (B) Scatter plot showed the relationship between the PCBAT AUC from the allergic groups and the corresponding natural log transformed dosage response slope. (C) PCBAT using cat allergen extracts were also performed on six atopic but non‐cat sensitized subjects, spearman test and <italic toggle="yes">R</italic> square was calculated and <italic toggle="yes">p</italic> &lt; .05 were considered significant.</p>
                      </caption>
                      <graphic xlink:href="CEA-53-405-g003" position="anchor" id="jats-graphic-5"/>
                    </fig>
                  </sec>
                </sec>
                <sec id="cea14251-sec-0030">
                  <label>3.1.4</label>
                  <title><styled-content style="fixed-case" toggle="no">PCBAT</styled-content> in peanut allergy</title>
                  <sec id="cea14251-sec-0031">
                    <title><styled-content style="fixed-case" toggle="no">PCBAT</styled-content> in confirmed peanut allergy</title>
                    <p>All adults with physician diagnosed peanut allergy (<italic toggle="yes">n</italic> = 30, Group 4) showed positive responses in PCBAT, which were dose‐dependent (Figure <xref rid="cea14251-fig-0004" ref-type="fig">4A</xref>), and all negative control subjects (<italic toggle="yes">n</italic> = 4) did not respond to peanut on PCBAT (Figure <xref rid="cea14251-fig-0004" ref-type="fig">4B</xref>). There was a significant correlation between PCBAT AUC and sIgE to whole peanut and Ara h 1, 2 (Figure <xref rid="cea14251-fig-0004" ref-type="fig">4C–E</xref>), 3 and 6 (Figures <xref rid="cea14251-supitem-0001" ref-type="supplementary-material">S11A,D</xref>) but not with sIgE to Ara h 8 and 9 (<italic toggle="yes">p</italic> &gt; .7; Figures <xref rid="cea14251-supitem-0001" ref-type="supplementary-material">S11B,C</xref>).</p>
                    <fig position="float" fig-type="FIGURE" id="cea14251-fig-0004">
                      <label>FIGURE 4</label>
                      <caption>
                        <p>PCBAT with peanut allergen extracts on physician diagnosed peanut allergic patients. PCBAT using peanut allergen extracts (1, 10, 100 or 1000 ng/ml) were performed on (A) 30 subjects with physician diagnosed peanut allergy, and (B) on four atopic but non‐peanut‐sensitized subjects. The relationship between the PCBAT AUC from the sensitized groups and the corresponding whole peanut sIgE level Ara h 1 sIgE level and Ara h 2 sIgE level were shown in scatter plot (C–E, respectively). Spearman test and <italic toggle="yes">R</italic> square was calculated and <italic toggle="yes">p</italic> &lt; .05 were considered significant.</p>
                      </caption>
                      <graphic xlink:href="CEA-53-405-g001" position="anchor" id="jats-graphic-7"/>
                    </fig>
                    <p>Of the 30 subjects with physician diagnosed peanut allergy (Group 4), half had confirmed peanut allergy following DBPCFC. Subjects who showed a higher PCBAT AUC reacted at a lower dose of peanut during DBPCFC (<italic toggle="yes">r</italic>
<sup>2</sup> = .57, <italic toggle="yes">p</italic> = .001, Figure <xref rid="cea14251-fig-0005" ref-type="fig">5A</xref>). A significant negative correlation was also observed between sIgE to Ara h 1 and oral food challenge results (<italic toggle="yes">r</italic>
<sup>2</sup> = .55, <italic toggle="yes">p</italic> = .007), but not with IgE to whole peanut (<italic toggle="yes">p</italic> = .094) or Ara h 2 sIgE (<italic toggle="yes">p</italic> = .125) (Figure <xref rid="cea14251-fig-0005" ref-type="fig">5B–D</xref>).</p>
                    <fig position="float" fig-type="FIGURE" id="cea14251-fig-0005">
                      <label>FIGURE 5</label>
                      <caption>
                        <p>PCBAT with peanut allergen extracts on peanut allergic subjects validated with oral peanut challenge. Of the 30 peanut allergic subjects performed with PCBAT, 15 underwent oral food challenge. Scatter plot showed the relationship between cumulative peanut dose to show first objective sign and PCBAT AUC (A) or sIgE to whole peanut (B), Ara h 1 (C) and Ara h 2 (D). Spearman test and R square was calculated and <italic toggle="yes">p</italic> &lt; .05 were considered significant.</p>
                      </caption>
                      <graphic xlink:href="CEA-53-405-g002" position="anchor" id="jats-graphic-9"/>
                    </fig>
                  </sec>
                  <sec id="cea14251-sec-0032">
                    <title><styled-content style="fixed-case" toggle="no">PCBAT</styled-content> in peanut‐sensitized but tolerant subjects</title>
                    <p>Within a population‐based birth cohort, we identified five subjects (Group 5) who were sensitized to 1 or more peanut allergen component (Ara h 1, 2, 3 or 6; Table <xref rid="cea14251-supitem-0001" ref-type="supplementary-material">S6</xref>), but self‐reported tolerance to peanut. No subjects showed responsiveness to peanut extracts in PCBAT even at the highest concentration (Figure <xref rid="cea14251-fig-0006" ref-type="fig">6</xref>).</p>
                    <fig position="float" fig-type="FIGURE" id="cea14251-fig-0006">
                      <label>FIGURE 6</label>
                      <caption>
                        <p>PCBAT with peanut allergen extracts on peanut‐sensitized but tolerant subjects PCBAT using peanut allergen extracts (1, 10, 100 or 1000 ng/ml) were performed on 5 peanut‐sensitized but tolerant subjects. Anti‐IgE was used as positive control stimulant for all tested serum samples. Spearman test and <italic toggle="yes">R</italic> square was calculated, <italic toggle="yes">p</italic> &lt; .05 were considered significant.</p>
                      </caption>
                      <graphic xlink:href="CEA-53-405-g006" position="anchor" id="jats-graphic-11"/>
                    </fig>
                  </sec>
                </sec>
              </sec>
            </sec>
            <sec sec-type="discussion" id="cea14251-sec-0033">
              <label>4</label>
              <title>DISCUSSION</title>
              <p>We have developed a high‐throughput progenitor cell‐derived basophil activation test (PCBAT), which was a better predictor of clinical reactivity to cat and peanut allergen (as measured on challenge testing) than conventional markers of allergy such as SPT or allergen specific IgE. PCBAT can be used with stored serum, removing the need for immediate access to expensive flow cytometry facilities not generally available in the clinic. By passively sensitizing basophils with sera from our well characterized patient populations then culturing with the relevant allergen, we demonstrated dose‐dependent and allergen specific basophil activation with wide variability in trajectories. PCBAT allows humoral factors to be investigated separately from cellular factors.</p>
              <sec id="cea14251-sec-0034">
                <label>4.1</label>
                <title>Technical aspects of the <styled-content style="fixed-case" toggle="no">PCBAT</styled-content>
</title>
                <p>The combined use of flow cytometry and immunostaining suggest the optimal window for maturation for this culture protocol was between day 16 and 21, consistent with the previous studies.<xref rid="cea14251-bib-0022" ref-type="bibr"><sup>22</sup></xref> Our culture was highly enriched for mature basophils (25%–50%), enabling high‐throughput barcoding and improved efficiency. Due to the lack of standardized cat allergen extract, we used cat skin prick test solution for PCBAT (ALK for Groups 1 and 2), and applied dilution factors for all the relevant abscissa. Where patients had undergone inhaled cat allergen challenge (Group 3), the same cat allergen extract for PCBAT was used (HollisterStier). Since the concentration of Fel d 1 in ALK allergen solution was twice that of HollisterStier (Figure <xref rid="cea14251-supitem-0001" ref-type="supplementary-material">S12</xref>), PCBAT comparison was not made between groups.</p>
              </sec>
              <sec id="cea14251-sec-0035">
                <label>4.2</label>
                <title><styled-content style="fixed-case" toggle="no">PCB</styled-content> responsiveness and <styled-content style="fixed-case" toggle="no">sIgE</styled-content> levels</title>
                <p>The PCBAT reaction was allergen specific, showing a dose‐dependent response with good association with levels of corresponding sIgE. In addition, patients receiving omalizumab treatment showed completely muted responsiveness in the PCBAT, in accordance with a previous study.<xref rid="cea14251-bib-0022" ref-type="bibr"><sup>22</sup></xref> However, one subject, with low but just‐detectable sIgE to cat (0.5 ku/L) did not show responsiveness in PCBAT; this patient was not on omalizumab treatment. As this subject had not undergone allergen challenge, it remains unclear whether this subject showed airway reactivity to cat allergen. One subject with sIgE to cat of &lt;0.35 ku/L, who had a positive dog sIgE (5 ku/L), showed minor degranulation on PCBAT but only at the highest concentration. We speculate that this weak response to cat allergen might reflect cross‐reactivity between cat allergen and dog sIgE, which has been previously reported.<xref rid="cea14251-bib-0023" ref-type="bibr"><sup>23</sup></xref>, <xref rid="cea14251-bib-0024" ref-type="bibr"><sup>24</sup></xref>, <xref rid="cea14251-bib-0025" ref-type="bibr"><sup>25</sup></xref> We have also found quantifiable traces of Can f 1 in both cat allergen extracts used (Figure <xref rid="cea14251-supitem-0001" ref-type="supplementary-material">S12</xref>).</p>
              </sec>
              <sec id="cea14251-sec-0036">
                <label>4.3</label>
                <title>Validation of <styled-content style="fixed-case" toggle="no">PCBAT</styled-content> in clinical allergy</title>
                <p>We validated PCBAT using two cohorts of patients who underwent inhaled cat allergen challenge or double blind placebo controlled oral food challenge of peanut.</p>
                <p>Although a significant association was observed between PCBAT AUC and allergen PC<sub>20</sub>, two subjects showed negative results in the PCBAT but reacted to inhaled cat allergen. It is noteworthy that as the blood samples were collected within 2 years of the inhaled allergen challenges, during which changes in allergen sensitivity and exposure is possible. Further prospective studies using sera collected near the time of inhaled allergen challenge and also sera from people with moderate and severe asthma is mandatory to confirm its role in predicting clinical reactivity.</p>
                <p>We explored PCBAT in peanut allergy as an exemplar of an allergic disease where clinical reactivity is not reliably predicted by serum sIgE, and oral food challenges are necessary to confirm allergy and quantify thresholds of responsiveness. All 30 patients with physician diagnosed peanut allergy showed a positive response in PCBAT; in addition, PCBAT showed a better correlation with threshold cumulative dose ingested during DBPCFC when compared with serum sIgE to whole peanut extract or to Ara h 2 and 3. Also, PCBAT were negative in a small number of patients that reported regularly eating peanuts but had positive sIgE to 1 or more peanut allergen component (Ara h 1, 2, 3 or 6). This suggests PCBAT may be a useful tool in differentiating individuals with peanut allergy from those who are sensitized but tolerant, but further testing on more subjects would be required for the evaluation of diagnostic and predictive powers. Also, it will be important to study the role of PCBAT in subjects sensitized only to Ara h 8 or Ara h 9, but stimulation would need to be with an extract containing high concentrations of these allergens, which occur at low concentration in the native food.</p>
              </sec>
              <sec id="cea14251-sec-0037">
                <label>4.4</label>
                <title>Limitations</title>
                <p>One of the major limitations of PCBAT is that the assay only focuses on the humoral factors whereas in a BAT where patient's own blood was used, the response is a combined effect from humoral and cellular factors.<xref rid="cea14251-bib-0026" ref-type="bibr"><sup>26</sup></xref>, <xref rid="cea14251-bib-0027" ref-type="bibr"><sup>27</sup></xref>, <xref rid="cea14251-bib-0028" ref-type="bibr"><sup>28</sup></xref> Therefore, PCBAT might not accurately simulate an allergic response as it does not take account of the between individual differences in native basophil reactivity. Although PCBAT has been evaluated against conventional diagnostic tests in allergy and demonstrates clear technical advantages over other basophil‐based effector cell assays, further studies are needed to directly compare the diagnostic powers of PCBAT with these assays and establish its clinical usefulness. Finally, we validated PCBAT in cat and peanut‐sensitized individuals, but its role in other allergies remains to be elucidated.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="cea14251-sec-0038">
              <label>5</label>
              <title>CONCLUSION</title>
              <p>By generating progenitor cell‐derived basophils in high‐yield we have developed a flow cytometry‐based basophil activation test for use with stored serum, which can be used to assess reactivity to both food and inhalant allergens. By incorporating fluorescent barcoding, we have increased the throughput of the assay significantly. We identified wide variability in trajectories of response to allergen in different subjects, and responses were muted in the presence of the anti‐IgE treatment omalizumab, indicating that this test better reflects the overall immune milieu rather than just specific IgE. For subjects who had undergone oral food challenge to peanut, we were able to use results of PCBAT to predict clinical reactivity to peanut. The correlation of PCBAT to clinical reactivity to inhaled cat allergen may represent a safe and robust way of identifying those asthmatics who might benefit from interventions for ongoing cat allergen exposure. Although further evaluation is required, this proof of concept study indicates that this test may have a role in food and inhalant allergy testing as a means of identifying clinically important sensitizations.</p>
            </sec>
            <sec id="cea14251-sec-0039">
              <title>AUTHOR CONTRIBUTION</title>
              <p>JW, AS and SBP designed the study and wrote the manuscript. JW, RB and MT designed experimental protocols. JW performed the experiments and analysis. ASJ and GVG performed OFC and subject selection of peanut tolerant and peanut allergic groups. GG and RC performed cat allergen inhalant challenge and MB and RW conducted subsequent data analysis and discussion. CM is the PI for the iFAAM study and provided peanut allergen. CSM and AC are the PIs of MAAS cohort and contributed to the editing of the manuscript. All authors contributed in revising the manuscript.</p>
            </sec>
            <sec sec-type="COI-statement" id="cea14251-sec-0041">
              <title>CONFLICT OF INTEREST</title>
              <p>The authors have no conflicts of interest to declare that are relevant to the content of this article.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="cea14251-supitem-0001" position="float" content-type="local-data">
                <caption>
                  <p>
Appendix S1.
</p>
                </caption>
                <media xlink:href="CEA-53-405-s001.docx"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="cea14251-sec-0040">
              <title>ACKNOWLEDGEMENT</title>
              <p>We would like to thank NIHR Manchester Biomedical Research Centre, MRC Confidence in Concept 2015 – University of Manchester (MC_PC_15038) and JP Moulton Charitable Foundation, and the North West Lung Centre Charity, Medical Research Council (MRC) G0601361 (2007–2012), MR/K002449/1 (2013–2014) and MR/L012693/1 (2014–2018) for providing funding support of this work. We would also like to thank Manchester Allergy, Respiratory &amp; Thoracic Surgery Biobank (ManARTS biobank) for providing the patient samples and clinical data. The clinical challenges were funded through the NIHR Clinical Research facility based at Manchester University NHS Foundation Trust and the European Union's Seventh Framework Program for research, technological development, and demonstration under grant agreement no. 312147 (Integrated Approaches to Food Allergen and Allergy Risk Management [iFAAM]). We also thank the Manchester Asthma and Allergy Study for providing the peanut tolerant samples and clinical data. Finally, we would like to thank Dr Gareth Howell for his invaluable help in flow cytometry technique, Dr Andrew Walls for supplying us with the BB1 antibody. Angela Simpson and Clare S Murray are supported by the Manchester Biomedical Research Centre.</p>
            </ack>
            <sec sec-type="data-availability" id="cea14251-sec-0043">
              <title>DATA AVAILABILITY STATEMENT</title>
              <p>All data generated or analysed during this study are included in this published article (and its supplementary information files).</p>
            </sec>
            <ref-list content-type="cited-references" id="cea14251-bibl-0001">
              <title>REFERENCES</title>
              <ref id="cea14251-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0001"><string-name><surname>He</surname><given-names>SH</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>HY</given-names></string-name>, <string-name><surname>Zeng</surname><given-names>XN</given-names></string-name>, <string-name><surname>Chen</surname><given-names>D</given-names></string-name>, <string-name><surname>Yang</surname><given-names>PC</given-names></string-name>. <article-title>Mast cells and basophils are essential for allergies: mechanisms of allergic inflammation and a proposed procedure for diagnosis</article-title>. <source>Acta Pharmacol Sin</source>. <year>2013</year>;<volume>34</volume>(<issue>10</issue>):<fpage>1270</fpage>‐<lpage>1283</lpage>.<pub-id pub-id-type="pmid">23974516</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0002"><string-name><surname>Kumar</surname><given-names>S</given-names></string-name>, <string-name><surname>Verma</surname><given-names>AK</given-names></string-name>, <string-name><surname>Das</surname><given-names>M</given-names></string-name>, <string-name><surname>Dwivedi</surname><given-names>PD</given-names></string-name>. <article-title>Molecular mechanisms of IgE mediated food allergy</article-title>. <source>Int Immunopharmacol</source>. <year>2012</year>;<volume>13</volume>(<issue>4</issue>):<fpage>432</fpage>‐<lpage>439</lpage>.<pub-id pub-id-type="pmid">22668720</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0003"><string-name><surname>Amin</surname><given-names>K</given-names></string-name>. <article-title>The role of mast cells in allergic inflammation</article-title>. <source>Respir Med</source>. <year>2012</year>;<volume>106</volume>(<issue>1</issue>):<fpage>9</fpage>‐<lpage>14</lpage>.<pub-id pub-id-type="pmid">22112783</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0004"><string-name><surname>MacGlashan</surname><given-names>DW</given-names><suffix>Jr</suffix></string-name>. <article-title>Basophil activation testing</article-title>. <source>J Allergy Clin Immunol</source>. <year>2013</year>;<volume>132</volume>(<issue>4</issue>):<fpage>777</fpage>‐<lpage>787</lpage>.<pub-id pub-id-type="pmid">23958648</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0005"><string-name><surname>Santos</surname><given-names>AF</given-names></string-name>, <string-name><surname>Lack</surname><given-names>G</given-names></string-name>. <article-title>Basophil activation test: food challenge in a test tube or specialist research tool?</article-title><source>Clin Transl Allergy</source>. <year>2016</year>;<volume>6</volume>:<fpage>10</fpage>.<pub-id pub-id-type="pmid">26981234</pub-id></mixed-citation>
              </ref>
              <ref id="cea14251-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0006"><string-name><surname>Okamoto</surname><given-names>S</given-names></string-name>, <string-name><surname>Taniuchi</surname><given-names>S</given-names></string-name>, <string-name><surname>Sudo</surname><given-names>K</given-names></string-name>, et al. <article-title>Predictive value of IgE/IgG4 antibody ratio in children with egg allergy</article-title>. <source>Allergy Asthma Clin Immunol</source>. <year>2012</year>;<volume>8</volume>(<issue>1</issue>):<fpage>9</fpage>.<pub-id pub-id-type="pmid">22676477</pub-id></mixed-citation>
              </ref>
              <ref id="cea14251-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0007"><string-name><surname>Santos</surname><given-names>AF</given-names></string-name>, <string-name><surname>James</surname><given-names>LK</given-names></string-name>, <string-name><surname>Bahnson</surname><given-names>HT</given-names></string-name>, et al. <article-title>IgG4 inhibits peanut‐induced basophil and mast cell activation in peanut‐tolerant children sensitized to peanut major allergens</article-title>. <source>J Allergy Clin Immunol</source>. <year>2015</year>;<volume>135</volume>(<issue>5</issue>):<fpage>1249</fpage>‐<lpage>1256</lpage>.<pub-id pub-id-type="pmid">25670011</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0008"><string-name><surname>Christensen</surname><given-names>LH</given-names></string-name>, <string-name><surname>Holm</surname><given-names>J</given-names></string-name>, <string-name><surname>Lund</surname><given-names>G</given-names></string-name>, <string-name><surname>Riise</surname><given-names>E</given-names></string-name>, <string-name><surname>Lund</surname><given-names>K</given-names></string-name>. <article-title>Several distinct properties of the IgE repertoire determine effector cell degranulation in response to allergen challenge</article-title>. <source>J Allergy Clin Immunol</source>. <year>2008</year>;<volume>122</volume>(<issue>2</issue>):<fpage>298</fpage>‐<lpage>304</lpage>.<pub-id pub-id-type="pmid">18572230</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0009"><string-name><surname>Hill</surname><given-names>DA</given-names></string-name>, <string-name><surname>Siracusa</surname><given-names>MC</given-names></string-name>, <string-name><surname>Ruymann</surname><given-names>KR</given-names></string-name>, <string-name><surname>Tait Wojno</surname><given-names>ED</given-names></string-name>, <string-name><surname>Artis</surname><given-names>D</given-names></string-name>, <string-name><surname>Spergel</surname><given-names>JM</given-names></string-name>. <article-title>Omalizumab therapy is associated with reduced circulating basophil populations in asthmatic children</article-title>. <source>Allergy</source>. <year>2014</year>;<volume>69</volume>(<issue>5</issue>):<fpage>674</fpage>‐<lpage>677</lpage>.<pub-id pub-id-type="pmid">24611974</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0010"><string-name><surname>Youssef</surname><given-names>LA</given-names></string-name>, <string-name><surname>Schuyler</surname><given-names>M</given-names></string-name>, <string-name><surname>Gilmartin</surname><given-names>L</given-names></string-name>, et al. <article-title>Histamine release from the basophils of control and asthmatic subjects and a comparison of gene expression between "releaser". And "nonreleaser" basophils</article-title>. <source>J Immunol</source>. <year>2007</year>;<volume>178</volume>(<issue>7</issue>):<fpage>4584</fpage>‐<lpage>4594</lpage>.<pub-id pub-id-type="pmid">17372017</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0011"><string-name><surname>Kepley</surname><given-names>CL</given-names></string-name>, <string-name><surname>Youssef</surname><given-names>L</given-names></string-name>, <string-name><surname>Andrews</surname><given-names>RP</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>BS</given-names></string-name>, <string-name><surname>Oliver</surname><given-names>JM</given-names></string-name>. <article-title>Syk deficiency in nonreleaser basophils</article-title>. <source>J Allergy Clin Immunol</source>. <year>1999</year>;<volume>104</volume>(<issue>2</issue>):<fpage>279</fpage>‐<lpage>284</lpage>.<pub-id pub-id-type="pmid">10452745</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0012"><string-name><surname>Pruzansky</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Grammer</surname><given-names>LC</given-names></string-name>, <string-name><surname>Patterson</surname><given-names>R</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>M</given-names></string-name>. <article-title>Dissociation of IgE from receptors on human basophils. I. Enhanced passive sensitization for histamine release</article-title>. <source>J Immunol</source>. <year>1983</year>;<volume>131</volume>(<issue>4</issue>):<fpage>1949</fpage>‐<lpage>1953</lpage>.<pub-id pub-id-type="pmid">6194222</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0013"><string-name><surname>Ishizaka</surname><given-names>T</given-names></string-name>, <string-name><surname>Ishizaka</surname><given-names>K</given-names></string-name>. <article-title>Mechanisms of passive sensitization. IV. Dissociation of IgE molecules from basophil receptors at acid pH</article-title>. <source>J Immunol</source>. <year>1974</year>;<volume>112</volume>(<issue>3</issue>):<fpage>1078</fpage>‐<lpage>1084</lpage>.<pub-id pub-id-type="pmid">4130108</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0014"><string-name><surname>Moneret‐Vautrin</surname><given-names>DA</given-names></string-name>, <string-name><surname>Sainte‐Laudy</surname><given-names>J</given-names></string-name>, <string-name><surname>Kanny</surname><given-names>G</given-names></string-name>, <string-name><surname>Fremont</surname><given-names>S</given-names></string-name>. <article-title>Human basophil activation measured by CD63 expression and LTC4 release in IgE‐mediated food allergy</article-title>. <source>Ann Allergy Asthma Immunol</source>. <year>1999</year>;<volume>82</volume>(<issue>1</issue>):<fpage>33</fpage>‐<lpage>40</lpage>.<pub-id pub-id-type="pmid">9988204</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0015"><string-name><surname>Passante</surname><given-names>E</given-names></string-name>. <article-title>Mast cell and basophil cell lines: a compendium</article-title>. <source>Methods Mol Biol</source>. <year>2014</year>;<volume>1192</volume>:<fpage>101</fpage>‐<lpage>113</lpage>.<pub-id pub-id-type="pmid">25149487</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0016"><string-name><surname>Custovic</surname><given-names>A</given-names></string-name>, <string-name><surname>Simpson</surname><given-names>BM</given-names></string-name>, <string-name><surname>Murray</surname><given-names>CS</given-names></string-name>, <string-name><surname>Lowe</surname><given-names>L</given-names></string-name>, <string-name><surname>Woodcock</surname><given-names>A</given-names></string-name>, <string-name><surname>Stu</surname><given-names>NMAA</given-names></string-name>. <article-title>The National Asthma Campaign Manchester Asthma and allergy study</article-title>. <source>Pediatr Allergy Immunol</source>. <year>2002</year>;<volume>13</volume>:<fpage>32</fpage>‐<lpage>37</lpage>.<pub-id pub-id-type="pmid">12688622</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0017"><string-name><surname>Cockcroft</surname><given-names>DW</given-names></string-name>, <string-name><surname>Davis</surname><given-names>BE</given-names></string-name>. <article-title>Methacholine PC20: 1‐point formula</article-title>. <source>Ann Allergy Asthma Immunol</source>. <year>2007</year>;<volume>98</volume>(<issue>5</issue>):<fpage>498</fpage>‐<lpage>499</lpage>.<pub-id pub-id-type="pmid">17521038</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0018"><string-name><surname>Nitride</surname><given-names>C</given-names></string-name>, <string-name><surname>Lee</surname><given-names>V</given-names></string-name>, <string-name><surname>Baricevic‐Jones</surname><given-names>I</given-names></string-name>, <string-name><surname>Adel‐Patient</surname><given-names>K</given-names></string-name>, <string-name><surname>Baumgartner</surname><given-names>S</given-names></string-name>, <string-name><surname>Mills</surname><given-names>ENC</given-names></string-name>. <article-title>Integrating allergen analysis within a risk assessment framework: approaches to development of targeted mass spectrometry methods for allergen detection and quantification in the iFAAM project</article-title>. <source>J AOAC Int</source>. <year>2018</year>;<volume>101</volume>(<issue>1</issue>):<fpage>83</fpage>‐<lpage>90</lpage>.<pub-id pub-id-type="pmid">29202914</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0019"><string-name><surname>Krutzik</surname><given-names>PO</given-names></string-name>, <string-name><surname>Nolan</surname><given-names>GP</given-names></string-name>. <article-title>Fluorescent cell barcoding in flow cytometry allows high‐throughput drug screening and signaling profiling</article-title>. <source>Nat Methods</source>. <year>2006</year>;<volume>3</volume>(<issue>5</issue>):<fpage>361</fpage>‐<lpage>368</lpage>.<pub-id pub-id-type="pmid">16628206</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0020"><string-name><surname>Matthews</surname><given-names>JN</given-names></string-name>, <string-name><surname>Altman</surname><given-names>DG</given-names></string-name>, <string-name><surname>Campbell</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Royston</surname><given-names>P</given-names></string-name>. <article-title>Analysis of serial measurements in medical research</article-title>. <source>BMJ</source>. <year>1990</year>;<volume>300</volume>(<issue>6719</issue>):<fpage>230</fpage>‐<lpage>235</lpage>.<pub-id pub-id-type="pmid">2106931</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0021"><string-name><surname>Kepley</surname><given-names>CL</given-names></string-name>, <string-name><surname>Pfeiffer</surname><given-names>JR</given-names></string-name>, <string-name><surname>Schwartz</surname><given-names>LB</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>BS</given-names></string-name>, <string-name><surname>Oliver</surname><given-names>JM</given-names></string-name>. <article-title>The identification and characterization of umbilical cord blood‐derived human basophils</article-title>. <source>J Leukoc Biol</source>. <year>1998</year>;<volume>64</volume>(<issue>4</issue>):<fpage>474</fpage>‐<lpage>483</lpage>.<pub-id pub-id-type="pmid">9766628</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0022"><string-name><surname>Eckman</surname><given-names>JA</given-names></string-name>, <string-name><surname>Sterba</surname><given-names>PM</given-names></string-name>, <string-name><surname>Kelly</surname><given-names>D</given-names></string-name>, et al. <article-title>Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge</article-title>. <source>J Allergy Clin Immunol</source>. <year>2010</year>;<volume>125</volume>(<issue>4</issue>):<fpage>889</fpage>‐<lpage>95 e7</lpage>.<pub-id pub-id-type="pmid">19962744</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0023"><string-name><surname>Viander</surname><given-names>M</given-names></string-name>, <string-name><surname>Valovirta</surname><given-names>E</given-names></string-name>, <string-name><surname>Vanto</surname><given-names>T</given-names></string-name>, <string-name><surname>Koivikko</surname><given-names>A</given-names></string-name>. <article-title>Cross‐reactivity of cat and dog allergen extracts. RAST inhibition studies with special reference to the allergenic activity in saliva and urine</article-title>. <source>Int Arch Allergy Appl Immunol</source>. <year>1983</year>;<volume>71</volume>(<issue>3</issue>):<fpage>252</fpage>‐<lpage>260</lpage>.<pub-id pub-id-type="pmid">6852948</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0024"><string-name><surname>Madhurantakam</surname><given-names>C</given-names></string-name>, <string-name><surname>Nilsson</surname><given-names>OB</given-names></string-name>, <string-name><surname>Uchtenhagen</surname><given-names>H</given-names></string-name>, et al. <article-title>Crystal structure of the dog lipocalin allergen can f 2: implications for cross‐reactivity to the cat allergen Fel d 4</article-title>. <source>J Mol Biol</source>. <year>2010</year>;<volume>401</volume>(<issue>1</issue>):<fpage>68</fpage>‐<lpage>83</lpage>.<pub-id pub-id-type="pmid">20621650</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0025"><string-name><surname>Nilsson</surname><given-names>OB</given-names></string-name>, <string-name><surname>Binnmyr</surname><given-names>J</given-names></string-name>, <string-name><surname>Zoltowska</surname><given-names>A</given-names></string-name>, <string-name><surname>Saarne</surname><given-names>T</given-names></string-name>, <string-name><surname>van Hage</surname><given-names>M</given-names></string-name>, <string-name><surname>Gronlund</surname><given-names>H</given-names></string-name>. <article-title>Characterization of the dog lipocalin allergen can f 6: the role in cross‐reactivity with cat and horse</article-title>. <source>Allergy</source>. <year>2012</year>;<volume>67</volume>(<issue>6</issue>):<fpage>751</fpage>‐<lpage>757</lpage>.<pub-id pub-id-type="pmid">22515174</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0026"><string-name><surname>MacGlashan</surname><given-names>DW</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Saini</surname><given-names>SS</given-names></string-name>. <article-title>Syk expression and IgE‐mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab</article-title>. <source>J Allergy Clin Immunol</source>. <year>2017</year>;<volume>139</volume>(<issue>5</issue>):<fpage>1680</fpage>‐<lpage>1682</lpage>. e10.<pub-id pub-id-type="pmid">28259446</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0027"><string-name><surname>Bahri</surname><given-names>R</given-names></string-name>, <string-name><surname>Custovic</surname><given-names>A</given-names></string-name>, <string-name><surname>Korosec</surname><given-names>P</given-names></string-name>, et al. <article-title>Mast cell activation test in the diagnosis of allergic disease and anaphylaxis</article-title>. <source>J Allergy Clin Immunol</source>. <year>2018</year>;<volume>142</volume>(<issue>2</issue>):<fpage>485</fpage>‐<lpage>496</lpage>. e16.<pub-id pub-id-type="pmid">29518421</pub-id>
</mixed-citation>
              </ref>
              <ref id="cea14251-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="cea14251-cit-0028"><string-name><surname>Santos</surname><given-names>AF</given-names></string-name>, <string-name><surname>Couto‐Francisco</surname><given-names>N</given-names></string-name>, <string-name><surname>Becares</surname><given-names>N</given-names></string-name>, <string-name><surname>Kwok</surname><given-names>M</given-names></string-name>, <string-name><surname>Bahnson</surname><given-names>HT</given-names></string-name>, <string-name><surname>Lack</surname><given-names>G</given-names></string-name>. <article-title>A novel human mast cell activation test for peanut allergy</article-title>. <source>J Allergy Clin Immunol</source>. <year>2018</year>;<volume>142</volume>(<issue>2</issue>):<fpage>689</fpage>‐<lpage>691</lpage>. e9.<pub-id pub-id-type="pmid">29731128</pub-id>
</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
